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A higher susceptibility of IDH1 mutant AML cells to mitochondrial inhibitors is due to 126 their enhanced OxPHOS activity. First we confirmed a higher sensitivity of IDH1/2-mutant 127 cells from primary AML patient samples (WT, n=64; MUT, n=56; TUH, BUH, IPC, 128 MDACC; Supplementary Table 1 ) and two genetically diverse cell lines to mitochondrial 129 inhibitors such as OxPHOS inhibitors, including a new electron transport chain (ETC) 130 complex I inhibitor IACS-010759 63 and metformin, ETC complex III (antimycin A, AA; 131 atovaquone, ATQ), ETC complex V (oligomycin, OLIGO) or BCL2 inhibitors 132 ABT-263) (Fig. 1a-c and Supplementary Fig. 1a ). Interestingly, their 2-HG response was 133 heterogeneous (Fig. 1d ). Whereas metformin induced an increase in 2-HG content, the BCL2 134 inhibitor ABT-199 caused a reduction in the amount of the oncometabolite. This strongly 135
suggests an enhancement of mitochondrial metabolic dependency in IDH mutant subgroup of 136 AML patients without a systematic correlation with 2-HG content. 137
To better understand why IDH1 mutant cells have a higher sensitivity to mitochondrial 138 inhibition, we extensively analyzed several biochemical, enzymatic and functional features 139 relative to mitochondrial activity in IDH1 mutant versus WT AML cells from two genetically 140 diverse AML cell lines in vitro and six patient-derived xenografts in vivo ( Supplementary Fig.  141 1b). Mitochondrial membrane potential, oxygen consumption, ATP-linked respiration and 142 ATP content were all significantly enhanced in IDH mutant AML cells in vitro and in vivo 143 ( Fig. 1e-g and Supplementary Fig. 1c-e ). Importantly, ETCI complex (and not other ETC 144 complexes) activity, NADH-producing enzyme activity of TCA enzymes such as malate 145 dehydrogenase (MDH2) and isocitrate dehydrogenase (IDH3) and concentration of Krebs 146 cycle intermediates (except α-KG) were also increased in IDH1 mutant AML cells ( Fig. 1h-j) , 147
indicating an increase in mitochondrial NADH availability, mitochondrial activities and 148
OxPHOS dependency specifically in IDH1 mutant AML cells. Interestingly, this was not due 149 to an increase in mitochondrial biogenesis as shown by mitochondrial mass, protein content of 7 ETC complexes, citrate synthase activity or ratio between mitochondrial and nucleic DNA, 151 which were not affected ( Supplementary Fig. 1f-j) . 152
Drug-resistant cancer cells have recently shown to be enriched in cells exhibiting a high 153
OxPHOS signature and enhanced mitochondrial function in several cancers including myeloid 154 malignancies 11, 12, 64, 65 . Accordingly, we observed that IDH1 mutant cells were more resistant 155 to conventional cytarabine (AraC) chemotherapy than IDH1 WT cells in vitro and in three 156 PDX models in vivo that are low responders ( Fig. 1k and Supplementary Fig. 1k ), as 157 previously defined to distinguish patients with high from low AraC response in vivo 11 . 158 159 Methylation-and CEBPα-dependent mitochondrial FAO is increased in IDH1 mutant 160 cells. In order to further identify the mitochondrial reprogramming induced by IDH1 161 mutation, we next performed a computational analysis of the metabolic network of IDH1 162 mutant cells based on human genome scale metabolic network reconstruction Recon2 (7440 163 metabolic reactions) 66 . To reconstruct active leukemic metabolic networks of IDH1 WT and 164 mutant AML cells at a global level, we integrated transcriptomic data and applied metabolic 165 constraints according to metabolite production and consumption rates measured in the 166 corresponding cell culture supernatants (exometabolome) 67,68 ( Fig. 2a ). This analysis 167 identified a significant enrichment of active reactions in various carbon metabolic pathways 168 (N-glycan synthesis, fructose and mannose metabolism, dicarboxylate metabolism; Fig. 2a ) in 169 IDH1 mutant cells and predicted a major change in FAO in these cells ( Fig. 2a-b ), especially 170 CPT1 which is required to initiate the transfer of fatty acids from the cytosol to the 171 mitochondrial matrix for oxidation ( Supplementary Fig. 2a ). This prediction prompted us to 172 assess key features of FA utilization in AML cells and patients with IDH1 mutation. First, we 173 measured acyl-CoAs as readout of FA catabolism. As expected, acetyl-CoA, succinyl-CoA, 174 reach the same level as before treatment (Fig. 3b ). In two AML cell lines harboring IDH1 250 mutation, AG-120 and AGI-5198 treatments significantly reduced 2-HG levels and decreased 251 the expressions of CEBPα, CPT1a, CPT2 and SLC25A20 ( Supplementary Fig. 3a-b) . 252
Furthermore, IDH1m inhibitors prevented the recruitment of endogenous CEBPα to promoter 253 of CPT1a, CPT2 and SLC25A20 ( Supplementary Fig. 3c ). As FAO is one of the major 254 biochemical pathways that support OxPHOS and mitochondrial function especially in 255 AML 5,11,74 , it was surprising to observe that IDH1m inhibitor maintained or even increased 256 FAO-coupled ( Fig. 3c ), basal mitochondrial ( Fig. 3d ) and ATP-linked OCR (Fig. 3e ). We 257 then assessed several mitochondrial activities after treatment with IDHm inhibitors. IDH1m 258 inhibitors also maintained or increased mitochondrial response in both IDH1 mutant cell lines 259 such as their mitochondrial membrane potential ( Supplementary Fig. 3d ), TCA cycle 260 intermediate concentrations ( Fig. 3f ), ETC complex activities or protein amounts 261 ( Supplementary Fig. 3e 
Treatment with OxPHOS inhibitors enhances anti-leukemic effects of IDH-mutant 267
specific inhibitors alone and in combination with cytarabine. We assessed several mono, 268 duplet or triplet therapeutic approaches in vivo with IDHm inhibitor AG-120 (150 mg/kg, 269 twice every day, 3 weeks), ETC complex I inhibitor IACS-010759 (8 mg/kg, every other day, 270 3 weeks) or/and AraC (30 mg/kg, every day, 1 week) in two IDH1 R132 PDX models with 271 variable engraftment capacity (high engrafting patient #325 in Fig. 4a -b, Supplementary Fig.  272 4; low engrafting patient #1065 in Supplementary Fig. 5a ). The level of 2-HG was greatly 273 reduced in the PDX sera upon all therapies compared to control group while α-KG remained 274 unchanged in PDX #325 (Fig 4c and Supplementary Fig. 4a ). Total cell tumor burden was 275 significantly reduced in mono, duplet and triplet therapy with a greater effect in the triplet 276 therapy cohort compared to vehicle cohort or AraC monotherapy ( Fig. 4d ). Similarly, 277 apoptosis was also increased in all treatments except AG-120 mono and duplet therapy with 278 IACS and we observed a greater significance in the triplet therapy compared to vehicle 279 ( Supplementary Fig. 4b ). Expression of the myeloid differentiation marker CD15 was also 280 significantly increased in duplet therapy combining AraC and IACS and even more in the 281 triplet therapy (Fig 4e and Supplementary Fig. 4c ). Interestingly, mitochondrial OxPHOS 282 function assessed in vivo by mitochondrial membrane potential was only decreased in the 283 triplet therapy ( Supplementary Fig. 4d ). Furthermore, mitochondrial ATP content and 284 respiratory capacities were increased after AraC or AG-120 alone or combined together but 285
rescued with the addition of IACS in the triplet therapy in vivo ( Fig. 4f and Supplementary 286
Fig. 4e-g). Analysis of mice serum metabolomes showed that aspartate level was significantly 287 reduced in all AraC groups, in particular in the duplet therapy with AG-120 and the triplet 288 therapy. Lactate level was enhanced in all groups with IACS including the triplet therapy as 289 key biomarker of IACS-010759 response ( Fig. 4g ). Similar in vivo experiments with lower 290 engrafting IDH1-R132 PDX showed a lower level in anti-leukemic and biological effects of 291 the mono, duplet and triplet combinations ( Supplementary Fig. 5 ). However and more 292 importantly in this low responder PDX, the triplet therapy induces a greater decrease in the 293 total cell tumor burden, in mitochondrial activity through decreased mitochondrial membrane 294 potential, mitochondrial ATP and enhanced lactate amount in mice sera ( Supplementary Fig.  295 5b-e). Of note, global toxicity of the triplet therapy or duplet therapies with AraC was 296 primarily driven by AraC toxicity ( Supplementary Fig. 4h -i and Fig. 5f -g). Altogether, these 297 results not only confirmed that IDHm inhibitor does not necessarily reverse metabolic and 298 mitochondrial (especially, enhanced OxPHOS phenotype) features of IDH mutant cells in 299 13 vivo but also that combining this drug with ETC complex I inhibitor in presence or not of 300 standard AraC chemotherapy increases its drug efficacy in vivo, notably by inducing a Pasteur 301 effect (e.g. increased lactate in response to the inhibition of mitochondrial ATP production). 302
Finally, taking advantage of this preclinical study, we have identified a set of metabolic 303 changes (here called AML metabolic profiling) that represent a combination of classic 304 hallmarks of the Pasteur effect and other metabolic adaptations to predict the response to IDH 305 plus OxPHOS inhibitors ( Supplementary Fig. 6 and Supplementary Table 2 ) and to monitor 306 the efficacy of their response ( Supplementary Table 3 ) in IDH mutant AML subgroup. 307 308
Discussion 309
Since the discovery of IDH mutations in various cancers, significant efforts have been 310 directed to understand the extent to which these oncogenic mutations directly impact 311 metabolism, histone/DNA methylation and gene expression 18,26,27,75-78 , cell proliferation and 312 differentiation bias 19,21-23,34 . However, questions remain unanswered related to the impact of 313 IDH mutation on mitochondrial energetic metabolism in IDH mutant cells. Here we address 314 several aspects of these different crucial points in IDH mutant cell biology and explain 315 mitochondrial dependency in the basal condition and upon IDHm inhibitor treatment. IDH 316 mutation induces mitochondrial reprogramming that contributes to maintain the pool of α-KG 317 to support 2-HG production and to replenish other Krebs cycle intermediates necessary for 318 anabolic reactions, oxygen consumption and ATP production by oxidative phosphorylation in 319 AML ( Fig. 4h ). Importantly, treatment with IDHm inhibitors transiently reverses FAO and 320
OxPHOS activities that are maintained or enhanced in non-responders or at relapse ( Fig. 4h ). 321
Several studies in different cancers have consistently shown increased mitochondrial 322 phenotypes in IDH mutant cells 59,61,79,80 . Our study helps to explain the dependence of IDH 323 mutant cells on mitochondria and energetic metabolism required to sustain mutant cell 324 proliferation, in particular for synthesis of α-KG and NADPH, the substrates of mutant IDH 325 enzyme activity. It is noteworthy that disturbances in cellular and mitochondrial metabolism 326 can contribute to the chemoresistance of AML cells 5,6,11 . Here we showed that IDH1 mutant 327 AML cells exhibited a higher OxPHOS phenotype than WT cells, consistent with a lower 328 response to AraC. We also observed a OxPHOS hyperactivity of IDH mutant cells and 329 confirmed a strong ETC1 complex dependency in AML 7,11,63,81,82 . Accordingly, mutant AML 330 cells exhibit enhanced vulnerabilities to various small molecules targeting mitochondrial 331
OxPHOS such as inhibitors of ETC complex I, III and V. Consistent with literature reports 332 and current clinical trials, we also observed that IDHm AML cells were more sensitive to 333 BCL2 inhibition by 62, 83 . Several combinations of BCL2i with newly approved 334 targeted therapies such as FLT3i and IDHi are under clinical assessment (NCT03735875 and 335 NCT03471260, respectively). Interestingly, 2-HG levels did not correlate with apoptosis in 336 these experiments, as its concentration decreased after ABT-199 while it increased after 337 metformin treatment, a result already observed in IDH1 R132H transformed mammary 338 epithelial cells 61 . This lack of correlation between cellular concentration of 2-HG, cell 339 survival and sensitivity to various inhibitors is of particular interest as it has been shown that 340 neither did inhibitors of mutant IDH reverse all IDH-mutant phenotypes nor did suppression 341 of 2-HG alone predict response to IDHm inhibitors 33, 44, 45, 59, 84, 85 . Our data and previous reports 342 clearly show that 2-HG is essential but insufficient in mediating and mimicking all the 343 complex metabolic consequences of IDH mutation 56,86 . These observations strongly suggest 344 that innovative combinatory therapies might be useful in this patient subgroup. Of particular 345 interest, whereas IDHm inhibitors maintain or increase mitochondrial and OxPHOS activity 346 in IDH mutant cell lines and primary patients in vitro, in vivo and in relapsed or refractory 347 AML patients in clinical trials, triplet combination using IDH1m inhibitor, OxPHOS inhibitor 348 (such as IACS-010759), and AraC showed promising effects in IDH1 mutant AML PDX. 349 Therefore, this triplet drug combination may represent a beneficial alternative for AML 350 patients unresponsive to IDH mutant-specific inhibitors. 351
In this regard, transcriptomic analysis before administration of an IDHm inhibitor in AML 352 patients with IDH mutation, at complete remission and at relapse and in patients who did not 353 respond to the drug revealed an enrichment in FAO and OxPHOS gene signatures at relapse 354 and in non-responders. In particular, expression of several genes participating in FAO such as 355
CPT1a, CPT2 and SLC25A20 correlate with relapse and response to IDHm inhibitor and 356 could potentially be used in clinics to predict and monitor the therapeutic efficacy of IDHm 357 and OxPHOS inhibitors. Moreover, we observed that lactate concentration in mice sera was 358 not modified and that mitochondrial ATP was maintained or increased by treatment with 359
IDH1m inhibitor alone while duplet or triplet therapies with OxPHOSi lead to significant 360 increase in lactate concentration and reduction in mitochondrial ATP in our high responder 361
PDX harboring IDH1 mutation. Accordingly, we proposed an AML metabolic profiling based 362 on measuring mitochondrial ATP, OxPHOS and FAO gene signatures from primary cells, and 363 lactate, aspartate and 2-HG in the sera of patients. This could represent a potentially powerful 364 tool in identifying and understanding dependence on individual mitochondrial FAO and 365
OxPHOS activities. Consequently, this combination of metabolic and genetic approaches can 366 also be used to predict and monitor responses to the duplet or triplet therapy combining IDHi 367
and OxPHOSi ( Supplementary Fig. 6 , Supplementary Table 2 and Supplementary Table 3 ) in 368 the context of the functional precision cancer medicine 87,88 . 369
Of particular interest, it was very recently shown that for patients with IDH1 or IDH2 370 mutation who responded to IDHm inhibitors in clinics and then relapsed, acquired resistance 371 to this molecularly targeted therapy was caused by the emergence of clones with a second-372 side IDH mutation in the wild type IDH allele without the initial IDH mutation, rescuing 2-373 HG production 48 . This reinforced the therapeutic interest/potential of our combinatory 374 strategy. Finally, our study supports the merit of future clinical trials testing the combination 375 of IDHm inhibitors and mitochondrial inhibitors with cytarabine treatment. Because this 376 proposed therapeutic strategy will overcome different newly identified mechanisms of 377 resistance to IDH mutant inhibitors 38,48,49 , this would be especially relevant as alternative 378 therapeutic approaches for the treatment of those patients that are not unresponsive to or 379 relapsing from IDH mutant-specific inhibitors. 
In vivo mice treatment 441
Eight to 18 weeks (PDX) after AML cell transplantation and when mice were engrafted 442 (tested by flow cytometry on peripheral blood or bone marrow aspirates), NSG mice were 443 treated as described below: 444
• AraC treatment: NSG mice were treated by daily intraperitoneal injection of 60 mg/kg 445 AraC for 5 days; AraC was kindly provided by the pharmacy of the TUH. For control, 446 NSG mice were treated daily with intraperitoneal injection of vehicle, PBS 1X. 447
• IACS-10759 treatment: IACS-10759 was solubilized in water containing 0.5% 448 methylcellulose before administration to mice. NSG mice were treated 3 times a week by 449 gavage of 8 or 5 mg/kg IACS-10759 (according to weight loss of mice) for 21 days. For 450 control, NSG mice were treated by daily gavage of vehicle. IACS-10759 was kindly 451 provided by Dr. Joe Marszalek. 452
• AG-120 treatment: AG-120 (Ivosidenib, AGIOS Pharmaceuticals) was solubilized in water 453 containing 0.5% methylcellulose and 0.2% Tween80 before administration to mice. NSG 454 mice were treated twice a day by gavage of 150mg/kg AG-120 for 21 days. For control, 455 NSG mice were treated twice a day by gavage of vehicle. 456
Mice were monitored for toxicity and provided nutritional supplements as needed. 457
Assessment of Leukemic Engraftment 458
Assessment of leukemic engraftment was measured as reported previously 11 . Briefly, NSG 459 mice were humanely killed in accordance with European ethics protocols. Bone marrow 460 
